Azorsa DO - Search Results

1

Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer.

Huusko P, Ponciano-Jackson D, Wolf M, Kiefer JA, Azorsa DO, Tuzmen S, Weaver D, Robbins C, Moses T, Allinen M, Hautaniemi S, Chen Y, Elkahloun A, Basik M, Bova GS, Bubendorf L, Lugli A, Sauter G, Schleutker J, Ozcelik H, Elowe S, Pawson T, Trent JM, Carpten JD, Kallioniemi OP, Mousses S. Huusko P, et al. Among authors: azorsa do. Nat Genet. 2004 Sep;36(9):979-83. doi: 10.1038/ng1408. Epub 2004 Aug 8. Nat Genet. 2004. PMID: 15300251

2

EphB2 expression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancers.

Lugli A, Spichtin H, Maurer R, Mirlacher M, Kiefer J, Huusko P, Azorsa D, Terracciano L, Sauter G, Kallioniemi OP, Mousses S, Tornillo L. Lugli A, et al. Clin Cancer Res. 2005 Sep 15;11(18):6450-8. doi: 10.1158/1078-0432.CCR-04-2458. Clin Cancer Res. 2005. PMID: 16166419

3

High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells.

Henderson MC, Gonzales IM, Arora S, Choudhary A, Trent JM, Von Hoff DD, Mousses S, Azorsa DO. Henderson MC, et al. Among authors: azorsa do. Mol Cancer Res. 2011 Jun;9(6):724-32. doi: 10.1158/1541-7786.MCR-10-0436. Epub 2011 May 2. Mol Cancer Res. 2011. PMID: 21536687 Free PMC article.

4

Functional evidence implicating S100P in prostate cancer progression.

Basu GD, Azorsa DO, Kiefer JA, Rojas AM, Tuzmen S, Barrett MT, Trent JM, Kallioniemi O, Mousses S. Basu GD, et al. Among authors: azorsa do. Int J Cancer. 2008 Jul 15;123(2):330-339. doi: 10.1002/ijc.23447. Int J Cancer. 2008. PMID: 18452169

5

Genome scale cytometry: High content analysis for high throughput RNAi phenotype profiling.

Evans DM, Azorsa DO, Mousses S. Evans DM, et al. Among authors: azorsa do. Drug Discov Today Technol. 2005 Summer;2(2):141-7. doi: 10.1016/j.ddtec.2005.05.012. Drug Discov Today Technol. 2005. PMID: 24981841

6

Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplification.

Kuuselo R, Savinainen K, Azorsa DO, Basu GD, Karhu R, Tuzmen S, Mousses S, Kallioniemi A. Kuuselo R, et al. Among authors: azorsa do. Cancer Res. 2007 Mar 1;67(5):1943-9. doi: 10.1158/0008-5472.CAN-06-3387. Cancer Res. 2007. PMID: 17332321

7

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.

Azorsa DO, Gonzales IM, Basu GD, Choudhary A, Arora S, Bisanz KM, Kiefer JA, Henderson MC, Trent JM, Von Hoff DD, Mousses S. Azorsa DO, et al. J Transl Med. 2009 Jun 11;7:43. doi: 10.1186/1479-5876-7-43. J Transl Med. 2009. PMID: 19519883 Free PMC article.

8

RNAi-based functional pharmacogenomics.

Tuzmen S, Tuzmen P, Arora S, Mousses S, Azorsa D. Tuzmen S, et al. Methods Mol Biol. 2011;700:271-90. doi: 10.1007/978-1-61737-954-3_18. Methods Mol Biol. 2011. PMID: 21204040

9

RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma.

Arora S, Gonzales IM, Hagelstrom RT, Beaudry C, Choudhary A, Sima C, Tibes R, Mousses S, Azorsa DO. Arora S, et al. Among authors: azorsa do. Mol Cancer. 2010 Aug 18;9:218. doi: 10.1186/1476-4598-9-218. Mol Cancer. 2010. PMID: 20718987 Free PMC article.

10

AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer.

Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS. Anzick SL, et al. Among authors: azorsa do. Science. 1997 Aug 15;277(5328):965-8. doi: 10.1126/science.277.5328.965. Science. 1997. PMID: 9252329

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

52 results

Search Page

Filters